TAS-102 and Bevacizumab as third line chemotherapy for colorectal cancer. Phase 2 trial
Latest Information Update: 14 Jun 2021
At a glance
- Drugs Bevacizumab (Primary) ; Tipiracil/trifluridine (Primary)
- Indications Adenocarcinoma; Colorectal cancer
- Focus Therapeutic Use
- Acronyms TAS-CC3
- 01 Jun 2021 Results of post-hoc analysis assessing predictive and prognostic values of pre-treatment blood inflammation-based scores, including the neutrophil-to-lymphocyte (NLR), platelet-to-lymphocyte (PLR) and lymphocyte-to-monocyte ratio (LMR) on disease-control (DC), PFS and OS, published in the Anticancer Research.
- 25 Jan 2020 Results of post hoc analysis assessing pretreatment lymphocyte-to-monocyte ratio (LMR) to predict treatment efficacy presented at the 2020 Gastrointestinal Cancers Symposium
- 19 Jan 2019 Primary endpoint (Progression free survival) has been met as per the results presented at the 2019 Gastrointestinal Cancers Symposium.